# Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

> **NCT01687920** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 25 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** BAY94-8862 (1.25mg)
- **DRUG:** BAY94-8862 (2.5mg)
- **DRUG:** BAY94-8862 (5mg)
- **DRUG:** BAY94-8862 (7.5mg)
- **DRUG:** BAY94-8862 (10mg)

## Key facts

- **NCT ID:** NCT01687920
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-17
- **Primary completion:** 2012-11-28
- **Final completion:** 2013-03-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687920, "Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01687920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*